Tumor-pH–Triggered Doxorubicin Prodrug with On-Demand Shelf-Stable Precursor
This invention introduces a small-molecule doxorubicin prodrug that remains inert in blood and rapidly activates in the mildly acidic tumor microenvironment. Featuring a shelf-stable maleimide pre-prodrug that converts on demand to the ultra-acid-labile DMA form, it enables targeted chemotherapy with improved selectivity, scalable synthesis, and reduced...
Published: 10/10/2025
|
Inventor(s): Ming An, Lan Yao, Vladyslav Nazarenko
Keywords(s): Technologies
Category(s): Campus > Binghamton University
|